Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection
BACKGROUND: Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentasvir (G/P) for hemodialysis patients showed high efficacy and safety; however, the number of GT2 HCV-infected patients, especially Asian patients, was limited and most of them were treated with a 12-week regimen. In this prospective multicenter study, we aimed to investigate the efficacy and safety of G/P in Japanese hemodialysis patients with GT2 HCV infection.
METHODS: Twenty-seven Japanese hemodialysis patients with GT2 HCV infection who were started on with 8- or 12-week G/P regimen between November 2017 and June 2018 were included and followed up for around 12 weeks after treatment completion.
RESULTS: Among the 27 included patients, 13 non-liver cirrhosis (LC) and direct-acting antivirals (DAAs)-naïve patients were treated with 8 weeks of G/P and 14 patients with LC (n = 13) or history of failure of DAAs (n = 1) were treated with a 12-week regimen. The overall sustained virological response at 12 weeks after treatment completion (SVR 12) was 96.3% (26/27). All patients with 8 weeks of treatment achieved SVR12. Two patients discontinued the therapy at 2 and 11 weeks after treatment initiation. The patient who discontinued at 2 weeks due to pruritus alone failed to respond to G/P. No patients experienced lethal adverse events during the therapy, and the most common adverse event was pruritus.
CONCLUSIONS: An 8- or 12-week G/P regimen is highly effective and safe in GT2 HCV-infected hemodialysis patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
---|---|
Enthalten in: |
Journal of gastroenterology - 54(2019), 7 vom: 18. Juli, Seite 641-649 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Suda, Goki [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiviral Agents |
---|
Anmerkungen: |
Date Completed 19.06.2020 Date Revised 19.06.2020 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00535-019-01556-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM294040382 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM294040382 | ||
003 | DE-627 | ||
005 | 20231225080633.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00535-019-01556-y |2 doi | |
028 | 5 | 2 | |a pubmed24n0980.xml |
035 | |a (DE-627)NLM294040382 | ||
035 | |a (NLM)30778716 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Suda, Goki |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.06.2020 | ||
500 | |a Date Revised 19.06.2020 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentasvir (G/P) for hemodialysis patients showed high efficacy and safety; however, the number of GT2 HCV-infected patients, especially Asian patients, was limited and most of them were treated with a 12-week regimen. In this prospective multicenter study, we aimed to investigate the efficacy and safety of G/P in Japanese hemodialysis patients with GT2 HCV infection | ||
520 | |a METHODS: Twenty-seven Japanese hemodialysis patients with GT2 HCV infection who were started on with 8- or 12-week G/P regimen between November 2017 and June 2018 were included and followed up for around 12 weeks after treatment completion | ||
520 | |a RESULTS: Among the 27 included patients, 13 non-liver cirrhosis (LC) and direct-acting antivirals (DAAs)-naïve patients were treated with 8 weeks of G/P and 14 patients with LC (n = 13) or history of failure of DAAs (n = 1) were treated with a 12-week regimen. The overall sustained virological response at 12 weeks after treatment completion (SVR 12) was 96.3% (26/27). All patients with 8 weeks of treatment achieved SVR12. Two patients discontinued the therapy at 2 and 11 weeks after treatment initiation. The patient who discontinued at 2 weeks due to pruritus alone failed to respond to G/P. No patients experienced lethal adverse events during the therapy, and the most common adverse event was pruritus | ||
520 | |a CONCLUSIONS: An 8- or 12-week G/P regimen is highly effective and safe in GT2 HCV-infected hemodialysis patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Genotype 2 | |
650 | 4 | |a Glecaprevir | |
650 | 4 | |a HCV | |
650 | 4 | |a Hemodialysis | |
650 | 4 | |a Pibrentasvir | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Benzimidazoles |2 NLM | |
650 | 7 | |a Drug Combinations |2 NLM | |
650 | 7 | |a Pyrrolidines |2 NLM | |
650 | 7 | |a Quinoxalines |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a glecaprevir and pibrentasvir |2 NLM | |
700 | 1 | |a Hasebe, Chitomi |e verfasserin |4 aut | |
700 | 1 | |a Abe, Masami |e verfasserin |4 aut | |
700 | 1 | |a Kurosaki, Masayuki |e verfasserin |4 aut | |
700 | 1 | |a Itakura, Jun |e verfasserin |4 aut | |
700 | 1 | |a Izumi, Namiki |e verfasserin |4 aut | |
700 | 1 | |a Uchida, Yoshihito |e verfasserin |4 aut | |
700 | 1 | |a Mochida, Satoshi |e verfasserin |4 aut | |
700 | 1 | |a Haga, Hiroaki |e verfasserin |4 aut | |
700 | 1 | |a Ueno, Yoshiyuki |e verfasserin |4 aut | |
700 | 1 | |a Abe, Kazumichi |e verfasserin |4 aut | |
700 | 1 | |a Takahashi, Atsushi |e verfasserin |4 aut | |
700 | 1 | |a Ohira, Hiromasa |e verfasserin |4 aut | |
700 | 1 | |a Tsukuda, Yoko |e verfasserin |4 aut | |
700 | 1 | |a Furuya, Ken |e verfasserin |4 aut | |
700 | 1 | |a Baba, Masaru |e verfasserin |4 aut | |
700 | 1 | |a Yamamoto, Yoshiya |e verfasserin |4 aut | |
700 | 1 | |a Kobayashi, Tomoe |e verfasserin |4 aut | |
700 | 1 | |a Inoue, Jun |e verfasserin |4 aut | |
700 | 1 | |a Terasita, Katsumi |e verfasserin |4 aut | |
700 | 1 | |a Ohara, Masatsugu |e verfasserin |4 aut | |
700 | 1 | |a Kawagishi, Naoki |e verfasserin |4 aut | |
700 | 1 | |a Izumi, Takaaki |e verfasserin |4 aut | |
700 | 1 | |a Nakai, Masato |e verfasserin |4 aut | |
700 | 1 | |a Sho, Takuya |e verfasserin |4 aut | |
700 | 1 | |a Natsuizaka, Mitsuteru |e verfasserin |4 aut | |
700 | 1 | |a Morikawa, Kenichi |e verfasserin |4 aut | |
700 | 1 | |a Ogawa, Koji |e verfasserin |4 aut | |
700 | 1 | |a Sakamoto, Naoya |e verfasserin |4 aut | |
700 | 0 | |a NORTE Study Group |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of gastroenterology |d 1994 |g 54(2019), 7 vom: 18. Juli, Seite 641-649 |w (DE-627)NLM074913832 |x 1435-5922 |7 nnns |
773 | 1 | 8 | |g volume:54 |g year:2019 |g number:7 |g day:18 |g month:07 |g pages:641-649 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00535-019-01556-y |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 54 |j 2019 |e 7 |b 18 |c 07 |h 641-649 |